<DOC>
	<DOCNO>NCT01191060</DOCNO>
	<brief_summary>Objective study determine , era novel drug , high dose therapy ( HDT ) still necessary initial management multiple myeloma young patient . HDT compare conventional dose treatment would consider superior significantly prolong Progression-free survival ( least 9 month ) .</brief_summary>
	<brief_title>Study Comparing Conventional Dose Combination RVD High-Dose Treatment With ASCT Initial Myeloma 65 Years</brief_title>
	<detailed_description>Study design Phase III , multicenter , randomize , open-label study design evaluate clinical benefit drug combination RVD without immediate high-dose therapy ( HDT ) follow lenalidomide maintenance ( Arm A ) versus RVD plus HDT PBSCT follow lenalidomide maintenance ( Arm B ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion Criteria registration : ( lab perform within 21 day initiation protocol therapy ) : Patients diagnose multiple myeloma base International Myeloma Foundation 2003 Diagnostic Criteria . Patients must symptomatic myeloma myelomarelated organ damage . Patients must myeloma measurable either serum urine evaluation monoclonal component assay serum free light chain . Age 18 65 year time signing informed consent document . ECOG performance status &lt; 2 ( Karnofsky ≥ 60 % ) Negative HIV blood test Exclusion Criteria registration ( section 4.2 ) : Participants must treat prior systemic therapy multiple myeloma . Treatment localize radiotherapy exclusion criterion interval least two week end radiotherapy initiation protocol therapy entry study observe . Similarly , dose corticosteroid receive participant exceed equivalent 160 mg dexamethasone twoweek period initiation protocol therapy . Primary amyloidosis ( AL ) myeloma complicate amylosis . Participants may receive study investigational agent . Participants know brain metastasis Poor tolerability know allergy study drug compound similar chemical biologic composition study agent Platelet count &lt; 50,000/mm3 per µLwithin 21 day initiation protocol therapy . Transfusion within 7 day screen allow meet platelet eligibility criterion . ANC &lt; 1,000 cells/mm3 within 21 day initiation protocol therapy . Growth factor within 7 day screen allow meet ANC eligibility criterion . Hemoglobin &lt; 8.0 g/dL within 21 day initiation protocol therapy . Transfusion may use meet hemoglobin eligibility criterion . Hepatic impairment , define bilirubin &gt; 1.5 x institutional upper limit normal ( ULN ) &gt; 2 mg/dL ( Patients benign hyperbilirubinemia ( e.g. , Gilbert 's syndrome ) eligible ) AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase &gt; 2 x ULN Renal insufficiency , define serum creatinine &gt; 2.5 mg/dl and/or creatinine clearance &lt; &lt; 40 60 ml/min ( actual calculate ) . The CockgroftGault formula use calculate creatinine clearance value , may locate Section 4.2 Respiratory compromise , define ventilation test DLCO &lt; 50 % Participant must demonstrate clinical sign heart coronary failure , evidence LVEF &lt; 40 % . Participant must myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA Appendix VII ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant . Intercurrent illness include , limited ongoing active severe infection , know ( active ) infection hepatitis B C virus , poorly control diabetes , severe uncontrolled psychiatric disorder psychiatric illness/social situation would limit compliance study requirement . Participant previous history another malignant condition , except basal cell carcinoma stage I cervical cancer Female participant pregnant breastfeeding Inability comply antithrombotic treatment regimen Peripheral neuropathy ≥ Grade 2 peripheral neuropathy clinical examination within 21 day initiation protocol therapy Mental illness likely interfere participation study Adults juridical protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Progression free survival prolongation</keyword>
	<keyword>Disease Progression</keyword>
	<keyword>Overall survival</keyword>
</DOC>